Table. 1.

Clinical profiles of the recipients

Case No. Age (yr) Sex Clinical presentation HBV infection Preoperative imaging diagnosis Preoperative biopsy MELD score AFP (ng/mL) DCP (mAU/mL) CA19-9 (ng/mL) Original HEHE-LT score Modified HEHE-LT score Tumor recurrence Disease-free survival period (mo) Recurrence treatment Survival status Overall patient survival period (mo)
1 41 F Jaundice No R/O EHE EHE-confirmed 19 4.1 56 40.1 10 2 Yes 2 Lung Mx+CTx Dead 9
2 39 F Abdominal pain No R/O EHE EHE-confirmed 10 1.3 26 9.8 8 1 No 105 No Alive 105
3 29 M Abdominal pain No R/O EHE EHE-confirmed 7 1.1 21 16 3 0 No 50 No Alive 50
4 56 F Routine health screening Yes R/O HCC,R/O EHE EHE-confirmed 7 2.2 21 25 3 0 No 47 No Alive 47

HBV, hepatitis B virus; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein; DCP, des-γ-carboxy prothrombin; CA 19-9, carbohydrate antigen 19-9; HEHE, hepatic epithelioid hemangioendothelioma; LT, liver transplantation; R/O, rule out; EHE, epithelioid hemangioendothelioma; Mx, metastasectomy; CTx, chemotherapy; HCC, hepatocellular carcinoma.

Korean J Transplant 2021;35:15~23 https://doi.org/10.4285/kjt.20.0049
© Korean Journal of Transplantation